



13. A pharmaceutical composition comprising a compound or salt of Claim 12 together with a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of Claim 13, wherein the composition comprises a therapeutically effective amount of an additional compound, wherein the additional compound is a therapeutic active agent.

15. A method of therapeutically treating hepatitis C infection in a patient, comprising providing a therapeutically effective amount of one or more compounds or salts thereof of Claim 1 to the patient.

16. A compound of Claim 12 of the formula



or a pharmaceutically acceptable salt thereof.

17. A compound of Claim 12 of the formula

22. A pharmaceutical composition comprising a compound or salt of Claim 18 together with a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a compound or salt of Claim 19 together with a pharmaceutically acceptable carrier.

24. A method of therapeutically treating hepatitis C infection in a patient having a hepatitis C infection, comprising providing a therapeutically effective amount of a compound or salt thereof of Claim 16 to the patient.


25. A method of therapeutically treating hepatitis C infection in a patient having a hepatitis C infection, comprising providing a therapeutically effective amount of a compound or salt thereof of Claim 17 to the patient.

26. A method of therapeutically treating hepatitis C infection in a patient having a hepatitis C infection, comprising providing a therapeutically effective amount of a compound or salt thereof of Claim 18 to the patient.

27. A method of therapeutically treating hepatitis C infection in a patient having a hepatitis C infection, comprising providing a therapeutically effective amount of a compound or salt thereof of Claim 19 to the patient.

28. The pharmaceutical composition of Claim 14, wherein the therapeutic active agent is a NS3a protease inhibitor.

29. The pharmaceutical composition of Claim 20, comprising an additional compound, wherein the additional compound is a therapeutic active agent or a salt thereof of the formula




13. A pharmaceutical composition comprising a compound or salt of Claim 12 together with a pharmaceutically acceptable carrier.

14. The pharmaceutical composition of Claim 13, wherein the composition comprises a therapeutically effective amount of an additional compound, wherein the additional compound is a therapeutic active agent.

15. The use of a therapeutically effective amount of one or more compounds or salts thereof of Claim 1 in the manufacture of a medicament for the treatment of hepatitis C infection.

16. A compound of Claim 12 of the formula



or a pharmaceutically acceptable salt thereof.

17. A compound of Claim 12 of the formula

22. A pharmaceutical composition comprising a compound or salt of Claim 18 together with a pharmaceutically acceptable carrier.

23. A pharmaceutical composition comprising a compound or salt of Claim 19 together with a pharmaceutically acceptable carrier.

24. The use of a therapeutically effective amount of a compound or salt thereof of Claim 16 in the manufacture of a medicament for the treatment of hepatitis C infection.

25. The use of a therapeutically effective amount of a compound or salt thereof of Claim 17 in the manufacture of a medicament for the treatment of hepatitis C infection.

26. The use of a therapeutically effective amount of a compound or salt thereof of Claim 18 in the manufacture of a medicament for the treatment of hepatitis C infection.

27. The use of a therapeutically effective amount of a compound or salt thereof of Claim 19 in the manufacture of a medicament for the treatment of hepatitis C infection.

28. The pharmaceutical composition of Claim 14, wherein the therapeutic active agent is a NS3a protease inhibitor.

29. The pharmaceutical composition of Claim 20, comprising an additional compound, wherein the additional compound is a therapeutic active agent or a salt thereof of the formula